Home Other Building Blocks 57381-26-7
57381-26-7,MFCD00866871
Catalog No.:AA00IA5E

57381-26-7 | Irsogladine

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$7.00   $5.00
- +
25mg
98%
in stock  
$9.00   $7.00
- +
250mg
98%
in stock  
$36.00   $25.00
- +
1g
98%
in stock  
$85.00   $60.00
- +
5g
98%
in stock  
$348.00   $244.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00IA5E
Chemical Name:
Irsogladine
CAS Number:
57381-26-7
Molecular Formula:
C9H7Cl2N5
Molecular Weight:
256.0914
MDL Number:
MFCD00866871
SMILES:
Clc1ccc(c(c1)c1nc(N)nc(n1)N)Cl
NSC Number:
759836
Properties
Computed Properties
 
Complexity:
232  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
16  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
1  
XLogP3:
2  

Literature

Title: The anti-ulcer agent, irsogladine, increases insulin secretion by MIN6 cells.

Journal: European journal of pharmacology 20120615

Title: Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium.

Journal: Medical molecular morphology 20120601

Title: Irsogladine maleate regulates epithelial barrier function in tumor necrosis factor-α-stimulated human gingival epithelial cells.

Journal: Journal of periodontal research 20120201

Title: Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.

Journal: Scandinavian journal of gastroenterology 20110301

Title: Irsogladine maleate regulates neutrophil migration and E-cadherin expression in gingival epithelium stimulated by Aggregatibacter actinomycetemcomitans.

Journal: Biochemical pharmacology 20100515

Title: Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study).

Journal: Alimentary pharmacology & therapeutics 20100401

Title: Irsogladine Maleate in the management of recurrent aphthous stomatitis: a pilot study.

Journal: Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry 20100101

Title: Effect of irsogladine maleate on NSAID-induced reduction of gastric mucosal blood flow in anesthetized dogs.

Journal: Digestion 20090101

Title: Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats.

Journal: Digestive diseases and sciences 20081001

Title: Irsogladine maleate abolishes the increase in interleukin-8 levels caused by outer membrane protein 29 from Aggregatibacter (Actinobacillus) actinomycetemcomitans through the ERK pathway in human gingival epithelial cells.

Journal: Journal of periodontal research 20081001

Title: Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats.

Journal: World journal of gastroenterology 20080814

Title: Irsogladine maleate counters the interleukin-1 beta-induced suppression in gap-junctional intercellular communication but does not affect the interleukin-1 beta-induced zonula occludens protein-1 levels in human gingival epithelial cells.

Journal: Journal of periodontal research 20080201

Title: Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis.

Journal: British journal of pharmacology 20070601

Title: Anti-inflammatory agents in the management of alimentary mucositis.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060601

Title: Regulation of IL-8 by Irsogladine maleate is involved in abolishment of Actinobacillus actinomycetemcomitans-induced reduction of gap-junctional intercellular communication.

Journal: Cytokine 20060601

Title: Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.

Journal: Arzneimittel-Forschung 20060101

Title: Irsogladine maleate influences the response of gap junctional intercellular communication and IL-8 of human gingival epithelial cells following periodontopathogenic bacterial challenge.

Journal: Biochemical and biophysical research communications 20050729

Title: Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.

Journal: Life sciences 20041119

Title: Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.

Journal: Life sciences 20040827

Title: Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.

Journal: Journal of pharmacological sciences 20040701

Title: Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.

Journal: Journal of pharmacological sciences 20031101

Title: Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis.

Journal: The Journal of rheumatology 20030901

Title: [A case of idiopathic relapsing aphthous stomatitis which was effectively treated by irsogladine maleate].

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011201

Title: Suppressive effect of irsogladine maleate on N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-initiated and glyoxal-promoted gastric carcinogenesis in rats.

Journal: Toxicology 20010914

Title: Ren, C.J., et al., Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res, 1998. 77(2): p. 126-31.

Title: Kawasaki, Y., et al., Irsogladine malate up-regulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas, 2002. 25(4): p. 373-7.

Title: Kyoi, T., et al., Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci, 2004. 75(15): p. 1833-42.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:57381-26-7 Molecular Formula|57381-26-7 MDL|57381-26-7 SMILES|57381-26-7 Irsogladine